Squamous cell carcinoma of the skin future or investigational therapies: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Squamous cell carcinoma}} | {{Squamous cell carcinoma}} | ||
{{CMG}}; '''Associate Editor(s)-in-Chief:''' [[User:Aditya Govindavarjhulla|Aditya Govindavarjhulla, M.B.B.S.]] [mailto:agovi@perfuse.org], [[User:Raviteja Reddy Guddeti|Raviteja Guddeti, M.B.B.S.]] [mailto:rgudetti@perfuse.org] | {{CMG}}; '''Associate Editor(s)-in-Chief:''' [[User:Aditya Govindavarjhulla|Aditya Govindavarjhulla, M.B.B.S.]] [mailto:agovi@perfuse.org], [[User:Raviteja Reddy Guddeti|Raviteja Guddeti, M.B.B.S.]] [mailto:rgudetti@perfuse.org] | ||
==Overview== | |||
== Future and Investigational treatment strategies == | == Future and Investigational treatment strategies == | ||
In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began [[clinical trials]] with a [[melanocyte-stimulating hormone]] called [[melanotan]] (known by the [[International Nonproprietary Name]] ''afamelanotide'', formerly CUV1647)<ref name="Clinuvel-INN">{{Cite web|url=http://www.clinuvel.com/resources/pdf/asx_announcements/2008/20080617WHOGenericName.pdf|title=World Health Organisation assigns CUV1647 generic name|accessdate=2008-06-17|publisher=Clinuvel|year=2008|format=[[Portable Document Format|PDF]]}}</ref> to provide [[photoprotection]] for organ transplant patients against squamous cell carcinoma of the skin and [[actinic keratosis]].<ref name="Clinuvel">[http://www.clinuvel.com/en/faqs/ Clinuvel » Investors » FAQs<!-- Bot generated title -->]</ref><ref name="PharmaAsia">[http://www.pharmaasia.com/article-6618-clinuvelsdrugbeginsglobalphaseiiskincancertrials-Asia.html PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials]</ref> | In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began [[clinical trials]] with a [[melanocyte-stimulating hormone]] called [[melanotan]] (known by the [[International Nonproprietary Name]] ''afamelanotide'', formerly CUV1647)<ref name="Clinuvel-INN">{{Cite web|url=http://www.clinuvel.com/resources/pdf/asx_announcements/2008/20080617WHOGenericName.pdf|title=World Health Organisation assigns CUV1647 generic name|accessdate=2008-06-17|publisher=Clinuvel|year=2008|format=[[Portable Document Format|PDF]]}}</ref> to provide [[photoprotection]] for organ transplant patients against squamous cell carcinoma of the skin and [[actinic keratosis]].<ref name="Clinuvel">[http://www.clinuvel.com/en/faqs/ Clinuvel » Investors » FAQs<!-- Bot generated title -->]</ref><ref name="PharmaAsia">[http://www.pharmaasia.com/article-6618-clinuvelsdrugbeginsglobalphaseiiskincancertrials-Asia.html PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials]</ref> | ||
Line 10: | Line 11: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 16:50, 28 August 2012
Squamous cell carcinoma of the skin Microchapters |
Differentiating Squamous cell carcinoma of the skin from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Squamous cell carcinoma of the skin future or investigational therapies On the Web |
American Roentgen Ray Society Images of Squamous cell carcinoma of the skin future or investigational therapies |
FDA on Squamous cell carcinoma of the skin future or investigational therapies |
CDC on Squamous cell carcinoma of the skin future or investigational therapies |
Squamous cell carcinoma of the skin future or investigational therapies in the news |
Blogs on Squamous cell carcinoma of the skin future or investigational therapies |
Directions to Hospitals Treating Squamous cell carcinoma of the skin |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Raviteja Guddeti, M.B.B.S. [3]
Overview
Future and Investigational treatment strategies
In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)[1] to provide photoprotection for organ transplant patients against squamous cell carcinoma of the skin and actinic keratosis.[2][3]
Cetuximab a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin, as initially suggested by case reports.
Use of natural agents in cancer therapy is increasing. For oral squamous cell carcinoma , use of curcumin microemulsions is under considerations. New modalities like use of ultra sound mediated delivery of these microemulsions. [4]
References
- ↑ "World Health Organisation assigns CUV1647 generic name" (PDF). Clinuvel. 2008. Retrieved 2008-06-17.
- ↑ Clinuvel » Investors » FAQs
- ↑ PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials
- ↑ Lenaz G, Fato R, Baracca A, Solaini G, Parenti Castelli G, Rabbi A (1988). "Dynamics of biological membranes". Ann. Ist. Super. Sanita. 24 (1): 9–21. PMID 3289448.